News

RIVANNA announces award from U.S. government to develop Accuro Platform for rapid triage of blast-related injuries

RIVANNA®, developers of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the design and development of a computer-aided 3D fracture detection and diagnosis product, called Accuro® XV. Under the contract 75A50121C00035, HHS/ASPR/BARDA will provide $11.6 million over 24 months with options for additional funding for supporting further development up to $65 million.

The project’s overarching objective is to achieve a market-ready, clinically proven and FDA-cleared Accuro XV product for rapid, radiation-free fracture detection and aid triage in emergency medicine; a critical medical countermeasure to ensure timely triage for reduction of morbidity and mortality in mass-casualty blast trauma incidents, for which, no field-deployable equipment for extremity fractures currently exists.

The Accuro XV is a portable medical system building on novel technologies that underpin RIVANNA’s extensive patent portfolio, including BoneEnhance® Multi-Frequency Image Reconstruction, which optimizes ultrasound for the visualization of bony versus soft-tissue anatomy. Supporting this image reconstruction technology is Multi-Probe Multi-Angle BoneVision™, an automated image-acquisition technique based on a series of novel three-dimensional ultrasound-based bone-imaging technologies that increases angular image sensitivity to bone surfaces. BoneVision provides precisely captured bony anatomical structures within a large field of view and demonstrated performance detecting small fractures with high sensitivity and specificity.

By automating both the image acquisition and image interpretation, Accuro XV will also support just-in-time training, ideal for mass-casualty incidents; the ease of use afforded by the automation will reduce user dependence and optimize the success of clinical evaluations for adoption in hospital and emergency room (ER) settings.

Will Mauldin, PhD, co-founder, and CEO of RIVANNA, commented, “We are pleased to receive this award from BARDA. With attainment of targeted product performance specifications, the clinical and economic value of Accuro XV is expected to result in an inevitable shift away from the current state of X-ray overutilization towards a radiation-free, bedside triage standard of care.”

 

To learn more please visit RIVANNA

Recent News

11/19/2021

Study aiming to define acute traumatic encephalopathy (ATE) published by leading neurology journal

BrainBox HeadSmart II Study Investigators Aim to Provide Clinicians with First-Ever Biomarkers and other Functional measurements for Acute Traumatic Encephalopathy (ATE.) A clinical trial of multi-modal diagnostic/prognostic test, already underway, is published in Frontiers in Neurology/NeuroTrauma. Investigators in a major clinical trial of patients with mild traumatic brain injury (mTBI or concussion) describe for the

11/17/2021

Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansion

Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, today announced two exceptional additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-generation of Ortho-K lens, Euclid MAX, is helping to combat the battle against

11/16/2021

HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda

HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company’s REVEAL-Tx™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited (“Takeda”) for further drug discovery activities for nonalcoholic steatohepatitis (NASH). This marks the successful completion of HemoShear’s exclusive collaboration with Takeda to discover novel targets and develop therapeutics for